HD-10019 / Harmonic Discovery - LARVOL DELTA

Preclinical characterization of HD10019, a FLT3 kinase inhibitor with optimized polypharmacology to treat FLT3-mutant AML (EORTC-NCI-AACR 2024) - "Approved FLT3 inhibitors midostaurin, gilteritinib and quizartinib increase mOS but suffer from adaptive resistance, myelosuppression, and/or cardiovascular safety issues. The selectivity of HD10019 supports improved resistant mutant coverage and reduced toxicities. The preclinical pharmacology represents a potential best-in-class profile to treat FLT3 mutant AML. HD10019 is currently entering IND development."

Preclinical • Acute Myelogenous Leukemia • Oncology • FLT3 • IRAK4 • KCNQ1OT1

Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program (PRNewswire) - "Harmonic Discovery...announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia (AML) from BioVentures (University of Arkansas for Medical Sciences) and UC San Francisco (UCSF). The compound, named HD-10019, is currently in pre-clinical development and is expected to commence IND-enabling studies in late 2024."

Licensing / partnership • Preclinical • Acute Myelogenous Leukemia